

MANAGEMENT OF ONCOGENIC TRANSFORMATION BY INTERFERING WITH THE ACTION OF ACTIVATOR PROTEIN-1

AKTİVATOR PROTEİN-1'İN ETKİSİNİ KULLANARAK ONKOJENİK TRANSFORMASYONU YÖNLENDİRMEK

Nurullah KEKLİKOĞLU*, Meltem KORAY**, İlker BOLAT*, Sevtap AKINCI *

ABSTRACT

Immediate Early Genes (IEGs) are the foremost genes to respond to any stimuli within the cell. This group of genes are in fact transcription factors which are associated with the growth, proliferation, differentiation and apoptosis of the cells. Fos proteins produced by c-fos gene, which is an IEG, and Jun proteins produced by c-jun gene, which is also an IEG, are the components of the transcription factor complex, namely the Activator Protein-1 (AP-1), and they act together. The members of the AP-1 complex modulate various gene expressions. All AP-1 proteins regulate certain aspects of the cellular responses to growth factors. These components are critically linked to many cellular processes including growth, proliferation, differentiation, apoptosis, and oncogenic transformation. Carcinogenesis resulting from the impairment in the cellular processes controlled by IEGs and AP-1 has been described. Besides the vital importance of their normal cellular expressions, the abnormal expressions of IEGs and AP-1 could cause serious problems such as oncogenic transformation. There are several ongoing studies about the substances and effectors causing overexpression or inhibition of AP-1. If the stages of oncogenic transformation and the role of AP-1 and IEGs in this transformation can be illuminated, carcinogenesis could be taken under control as well as some of the peculiarities of malignant cells could be beneficial for the treatments of various diseases.

Key words: IEGs, AP-1, Carcinogenesis, Proto-oncogenes, Oncoproteins, Oncogenic transformation.

ÖZET

Bir uyarıla karşılaşan hücrelerde, uyarana ilk yanıt veren genler IEG (Immediate Early Gene) grubundaki genlerdir. Bu genler hücre büyümesi, çoğalması, farklılaşması ve hücrenin programlanmış ölümü (apoptozis) ile ilgili transkripsiyon faktörleridir. Bir IEG olan c-fos geninin ürettiği Fos proteinleri, yine bir IEG olan c-jun geninin ürettiği Jun proteinleri transkripsiyon faktör kompleksi Aktivator Protein-1 (AP-1)'in komponentleri olarak birlikte işlev görürler. AP-1 kompleksinin üyeleri farklı gen ekspresyonlarını ve büyümeye faktörlerine hücresel yanıtın bazı yönlerini düzenlerler. Bu komponentler büyümeye, çoğalma, farklılaşma, programlanmış hücre ölümü ve onkojenik transformasyon gibi hücresel süreçlerde kilit rolü oynarlar. Karsinogenezin, IEG ve AP-1 tarafından kontrol edilen hücresel süreçlerdeki bozukluğun bir sonucu olduğu tanımlanmıştır. IEG ve AP-1'in hücrelerdeki normal ekspresyonlarının yaşamsal önemi vardır ancak anormal ekspresyonları, onkojenik transformasyon gibi ciddi sorunlar doğurur. AP-1'in ekspresyonunu artıran veya azaltan maddeler ve etkenler konusundaki çalışmalar devam etmektedir. Onkojenik transformasyonun aşamaları ve bu transformasyonda IEG ve AP-1'in rolü tam olarak aydınlatılabilirse karsinogenez kontrol edilebilir bir duruma gelebilecek hatta kanser hücrelerinin bazı özelliklerinden çeşitli hastalıkların tedavisinde yararlanılabilecektir.

Anahtar kelimeler : IEG, AP-1, Karsinogenez, Protoonkojenler, Onkoproteinler, Onkojenik transformasyon.

INTRODUCTION

Immediate Early Genes (IEGs) and Activator Protein -1 (AP-1) family proteins which contain their oncoprotein products, are required for the maintenance of the vitality

and regeneration of cells. Besides the vital importance of their normal cellular expressions, the abnormal expressions of IEGs and AP-1 could cause serious problems such as oncogenic transformation. If the role of AP-1 in onco-

Dergiye geldiği tarih/ Date received: 12.03.2007 - Dergiye kabul edildiği tarih: 17.08.2007

* İstanbul Üniversitesi, Diş Hekimliği Fakültesi, Histoloji ve Embriyoji Bilim Dalı, İstanbul
(İletişim kurulacak yazar: nkeklik@istanbul.edu.tr)

** İstanbul Üniversitesi, Diş Hekimliği Fakültesi, Ağzı, Diş-Çene Hastalıkları Bilim Dalı, İstanbul




Figure 1. Signal transduction activation of Activator Protein-1 (AP-1)

genic transformation can be elucidated, characteristics of cancer cells could be utilized in the treatments of various disorders.

IEGs are potential activators of transcription and IEGs are the first genes to respond to any stimuli within the cell (7). IEGs and AP-1, play a very important role during cellular proliferation, differentiation, programmed cell death (apoptosis) and oncogenic transformation (4, 41). These proto-oncogenes and oncoproteins, being potential activators of transcription, are key elements to understand oncogenic transformation and normal development due to their relationship with biological processes. The pathways regulating different cell cycle phases are the central target for genetic alterations in cancer due to their interaction with various oncogenes and tumor suppressors (15). The transcription factors are fundamental to the progression of genetic and cellular changes which culminate in a malignant tumor (40). In some tumor types, c-fos and c-jun levels, both of which are IEGs, have been shown to increase, and it was suggested that this elevation may play an important role in tumorigenesis, since it is a sign of increased proliferation (14, 27). However, in addition to their role in malignancy, proto-oncogenes are also involved in the regulation of normal growth and differentiation.

Many mitogens may stimulate IEGs, and therefore the protein product of these proto-oncogenes are referred to as

oncoproteins. These proteins are known to play a role in the development of cancer (46). Fos proteins produced by c-fos gene and Jun proteins produced by c-jun gene are the components of the transcription factor complex, namely the Activator Protein-1 (AP-1) (16). AP-1 consists of Fos proteins (c-Fos, Fos B, Fra 1, and Fra 2), Jun proteins (c-Jun, Jun B, and Jun D), and some activating transcription factor (ATF) proteins (ATFa, ATF-1, ATF-2, and ATF-3) (12, 25). Fos proteins form stable dimers with Jun proteins. On the other hand, Jun proteins form homodimers or heterodimers with Fos and ATF proteins (2, 14, 25). All AP-1 proteins are phosphoproteins and their DNA-binding properties and transactivation activities may be influenced by hyperphosphorylation and dephosphorylation (13). Each AP-1 dimer may be linked with various specific stages of cellular process, rather than the entire process (26).

The components of AP-1 complex bind to the promoter regions on DNA that contain 12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (TRE) to modulate various gene expressions (2). AP-1 is crucial for cell adaptation to many environmental changes (5). All AP-1 proteins regulate certain aspects of the cellular response to growth factors and tumor promoting phorbol esters (2). These stimulants can stimulate AP-1 activity by activating mitogen-activated protein kinases (MAPK), such as extracellu-

lar signal-regulated kinase (ERK), c-Jun N-terminal kinase or stress-activated protein kinase (JNK/SAPK) and p38 kinase (19). Induced AP-1 activity is required for tumor promoter-induced transformation (10) (Figure 1). It is known that IEGs and AP-1 are key factors in carcinogenesis (18, 37, 50). Carcinogenesis develops in three defined stages; initiation, promotion, and progression (36). Transactivation of AP-1 is important in traversing tumor promotion and/or progression stages of carcinogenesis (50). According to a claim, c-fos expression is involved in benign-to-malignant tumor progression (17).

It is possible to block carcinogenesis or inactivate cancer cells by inhibiting the transcriptional activity of AP-1 or AP-1 expression. Since AP-1 inhibitors respond to peptide growth factors like insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), heregulin-beta and basic fibroblast growth factor (bFGF) by completely blocking proliferation, AP-1 blockade suppresses mitogenic signal from multiple different peptide growth factors (31). The incidence of cancer increases with age (3). A possible contributing factor may be that the level of AP-1 activity varies throughout the life time of both a cell and an individual. It has been suggested that IEG and AP-1 activity, which are high during embryonic development, may be altered by ageing. Cellular ageing results in significant changes in the composition and DNA-binding capacity of AP-1 transcription factor (43). Cellular ageing is characterized by many phenotypic changes such as the alteration in the proliferative capacity of gene expression, impairment in the stimulation of c-fos by serum, and alterations in the binding activity of Serum Response Factor (SRF). These changes are associated with decrease in c-fos expression in the older cells (32, 47).

According to the results of some studies, AP-1 proteins can substitute each others antagonistic functions in biological processes such as oncogenic transformation and cell proliferation and each of AP-1 proteins may have different individual functions (23, 26, 44). There are some different implications for these transcription factors according to tumour type, for example, Fra-1 overexpression enhances the motility and invasion of breast and colorectal cancer cells, but inhibits the tumorigenicity of cervical carcinoma cell lines (35). It is also claimed that some proteins belonging to Jun and Fos families, like Jun B and c-Fos, have tumour-suppressor activity and can suppress tumour formation. The decision as to whether AP-1 is oncogenic or anti-oncogenic depends on the cell type, differentiation state, tumour stage and the genetic background of the tumour (11).

The genes some of which have a potential to mediate neoplastic transformation, are regulated by AP-1 (1). Therefore the studies to determine substances and mechanisms which are able to inhibit AP-1 activation are crucial steps in the progress of controlling carcinogenesis (21, 29, 31, 52). There are ongoing studies pointing that the biologic mechanisms or curative substances inhibit growth or inva-

sion in cancer cells through repression or blocking of AP-1 activity (6, 20, 22, 34, 39, 49). It is known that dominant-negative cJun mutant (TAM67) (18, 31, 34) and Jun dimerization protein 2 (JDP2) (32) are specific inhibitors of AP-1. It has been reported that TAM67 inhibits breast cancer growth by inducing inhibitors of cyclin-dependent kinases (such as p27) and by reducing the expression of the cyclins involved in transitioning from G1 into S phase of the cell cycle (30). It has been shown that protein kinase C (PKC) inhibitors like Calphostin C and bisindolylmaleimide I also inhibit AP-1 activation and phosphorylation of MAPKs (ERKs and p38 kinases) (9).

TRIM45 one of the tripartite motif (TRIM) proteins (48), Costunolide, a sesquiterpene lactone isolated from the root of Saussurea lapa Clarke [24], Gabexate mesilate, a synthetic protease inhibitor (51), Rhein (4,5-Dihydroxyanthraquinone-2-carboxylic acid), a constituent enriched in the rhizome of rhubarb (*R. palmatum* L. or *R. tanguticum* Maxim) (29), inhibit the activity of AP-1 transcription factor.

According to the result of a previously performed study; inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth (31). Moreover, different cases about blocking AP-1 activity have also been reported in another studies, including blocking AP-1 activation using Ursodeoxycholic acid (UDCA) in order to block colonic carcinogenesis (42), inhibition of breast cancer cell growth by means of using overexpression of TAM67 (a dominant-negative form of cJun) (33) and inhibition of both AP-1 activation and translation initiation by programmed cell death 4 (PDCD4) while decreasing benign tumor development and malignant progression (21).

By AP-1 inhibition, it is possible to inhibit matrix metalloproteinases (MMPs) which are important factors in tumor invasion and metastasis. Treatment of human fibrosarcoma cells with Carboxylated chitooligosaccharides (CCOS) leads to down-regulation of AP-1, which results in inhibition of matrix metalloproteinase-9 (MMP-9) (38). Moreover, treatment of human breast carcinoma cells with silibinin, a flavonoid antioxidant from milk thistle (*Silybum marianum* L.) suppresses AP-1 dependent MMP-9 gene expression by blocking the activation of AP-1 via MAPK signaling pathways (28).

Carcinogenesis resulting from the impairment in the cellular processes controlled by IEGs and AP-1 has been described. The abnormal expressions of oncogenes, oncoproteins and tumor suppressors disorder normal cell cycle. This incident brings new characteristics to these cells. The ability of a tumor cell to avoid programmed cell death (apoptosis) is crucial in the development of cancer (8). The acquisition of cellular immortality is a crucial step in human tumorigenesis (45).

Systemic activation or inactivation of IEGs and AP-1 may help to control the carcinogenesis invoked by inadequate or over-activation of IEGs and AP-1. The carcinogenesis progress can also be taken under control by analyzing and

fully revealing cancer cell characteristics such as immortality-evasion from apoptosis, metastasis, continuous division-proliferation and unaging. By controlling this process, mentioned peculiarities of cancer cells can be utilized to discover new treatment approaches or develop current treatment procedures. Therefore it may be possible to prevent cell and tissue based disorders such as cell-ageing, growth retardation and it may be also possible to compensate loss of tissue integrity due to several reasons.

REFERENCES

- 1- Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. *Cell* 1987;49:729-739.
- 2- Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochem Biophys Acta* 1991;1072:129-157.
- 3- Anisimov VN. Biology of aging and cancer. *Cancer Control* 2007;14:23-31.
- 4- Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. *Mol Cell Biol* 2002;22:4952-4964.
- 5- Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind R, Rodriguez M, Schmidt D, Muller S, Jariel-Encontre I, Piechaczyk M. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. *Mol Cell Biol* 2005;25:6964-6979.
- 6- Chun KS, Kim SH, Song YS, Surh YJ. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. *Carcinogenesis* 2004;25:713-722.
- 7- Clayton DF. The genomic action potential. *Neurobiol Learn Mem.* 2000;74:185-216.
- 8- Crighton D, Ryan KM. Splicing DNA-damage responses to tumour cell death. *Biochim Biophys Acta* 2004;1705:3-1715.
- 9- Ding M, Huang C, Lu Y, Bowman L, Castranova V, Vallyathan V. Involvement of protein kinase C in crystalline silica-induced activation of the MAP kinase and AP-1 pathway. *Am J Physiol Lung Cell Mol Physiol* 2006;290:291-297.
- 10- Dong Z, Birer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. *Proc Natl Acad Sci USA* 1994;91:609-613.
- 11- Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. *Nat Rev Cancer* 2003;3:859-868.
- 12- Fleischmann A, Hafezi F, Elliott C, Reme EC, Rüther U, Wagner FE. Fra-1 replaces c-Fos-dependent functions in mice. *Genes & Dev* 2000;14:2695-2700.
- 13- Foletta VC. Transcription factor AP-1, and the role of Fra-2. *Immunol Cell Biol* 1996;74: 121-133.
- 14- Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. *Virchows Arch*. 1998;432:515-519.
- 15- Funk JO. Cancer cell cycle control. *Anticancer Res* 1999;19:4772-4780.
- 16- Glover JNM, Harrison SC. Crystal structure of the Heterodimeric bZIP Transcription Factor c-Fos/ c-Jun Bound to DNA. *Nature* 1995;373:257-261.
- 17- Greenhalgh DA, Wang XJ, Eckhardt JN, Roop DR. 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy. *Cell Growth Differ* 1995;6:579-586.
- 18- Hennigan RF, Stambrook PJ. Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. *Mol Biol Cell* 2001;12:2352-2363.
- 19- Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, Fujii M, Young MR, Colburn N. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms. *Carcinogenesis* 2004;25:29-36.
- 20- Huang Q, Shen HM, Ong CN. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. *Biochem Pharmacol* 2004;68:361-371.
- 21- Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. *Cancer Res* 2005;65:6034-6041.
- 22- Jin C, Li H, Murata T, Sun K, Horikoshi M, Chiu R, Yokoyama KK. JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. *Mol Cell Biol* 2002;22:4815-4826.
- 23- Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. *Oncogene* 2001;20:2401_2412.
- 24- Kang JS, Yoon YD, Lee KH, Park SK, Kim HM. Costunolide inhibits interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells. *Biochem Biophys Res Commun* 2004;313:171-177.
- 25- Karin M, Zhend-gang L, Zandi E. AP-1 function and regulation. *Curr Opin Cell Biol* 1997;9:240-246.
- 26- Keklikoglu N. The localization of Fos B, a member of transcription factor AP-1 family, in rat odontoblasts and pulpal undifferentiated ectomesenchymal cells. *Folia Histol Cytobiol* 2004;42:191-193.
- 27- Lee CS, Charalambous D. Immunohistochemical localisation of the c-fos oncprotein in pancreatic cancer. *Zentralbl Pathol* 1994;140:271-275.
- 28- Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. *Biochem Biophys Res Commun* 2007;354:165-171.
- 29- Lin S, Li JJ, Fujii M, Hou DX. Rhein inhibits TPA-induced activator protein-1 activation and cell transformation by blocking the JNK-dependent pathway. *Int J Oncol* 2003;22:829-833.
- 30- Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1cyclin expression and reducing cyclin-dependent kinase activity. *Oncogene* 2004;23:8238-8246.

- 31- Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. *Oncogene* 2002;21:7680-7689.
- 32- Lorenzini A, Tresini M, Mawal-Dewan M, Frisoni L, Zhang H, Allen RG, Sell C, Cristofalo VJ. Role of the Raf/MEK/ERK and the PI3K/Akt(PKB) pathways in fibroblast senescence. *Exp Gerontol* 2002;37:1149-1156.
- 33- Lu C, Shen Q, Dupre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. *Oncogene* 2005;24:6516-6524.
- 34- Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. *Oncogene* 2001;20:2771-2780.
- 35- Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. *Eur J Cancer* 2005;41:2449-2461.
- 36- Pitot HC. Multistage carcinogenesis--genetic and epigenetic mechanisms in relation to cancer prevention. *Cancer Detect Prev* 1993;17:567-573.
- 37- Qi X, Borowicz S, Pramanik R, Schultz RM, Han J, Chen G. Estrogen receptor inhibits c-Jun-dependent stress-induced cell death by binding and modifying c-Jun activity in human breast cancer cells. *J Biol Chem* 2004;279:6769-6777.
- 38- Rajapakse N, Kim MM, Mendis E, Huang R, Kim SK. Carboxylated chitooligosaccharides (CCOS) inhibit MMP-9 expression in human fibrosarcoma cells via down-regulation of AP-1. *Biochim Biophys Acta* 2006;1760:1780-1788.
- 39- Ramirez CJ, Haberbusch JM, Soprano DR, Soprano KJ. Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells. *J Cell Biochem* 2005;96:170-182.
- 40- Redell MS, Twardy DJ. Targeting transcription factors for cancer therapy. *Curr Pharm Des* 2005;11:2873-2887.
- 41- Roche E, Buteau J, Aniento I, Reig JA, Soria B, Prentki M. Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. *Diabetes* 1999;48:2007-2014.
- 42- Shah SA, Volkov Y, Arfin Q, Abdel-Latif MM, Kelleher D. Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells. *Int J Cancer* 2006;118:532-539.
- 43- Sheerin A, Thompson KS, Goyns MH. Altered composition and DNA binding activity of the AP-1 transcription factor during the ageing of human fibroblasts. *Mol Ageing Dev* 2001;122:1813-1824.
- 44- Shirsat NV, Shaikh SA. Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells. *Exp Cell Res* 2003;291:91-100.
- 45- Stewart SA. Telomere maintenance and tumorigenesis: an "ALT"ernative road. *Curr Mol Med* 2005;5:253-257.
- 46- de Sousa SO, Mesquita RA, Pinto DS Jr, Gutkind S. Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. *J Oral Pathol Med* 2002;31:78-81.
- 47- Tresini M, Lorenzini A, Frisoni L, Allen RG, Cristofalo VJ. Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast. *Exp Cell Res* 2001;269:287-300.
- 48- Wang Y, Li Y, Qi X, Yuan W, Ai J, Zhu C, Cao L, Yang H, Liu F, Wu X, Liu M. TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of Elk-1 and AP-1. *Biochem Biophys Res Commun* 2004;323:9-16.
- 49- Wu Q, Chen Z, Su W. Mechanism of inhibition on activator protein-1 activity by all-trans retinoic acid in gastric cancer cells. *Chin Med J (Engl)* 2000;113:972-976.
- 50- Young MR, Li JJ, Rincon M, Flavell RA, Sathyamaranayana BK, Hunziker R, Colburn N. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. *Proc Natl Acad Sci U S A*. 1999 ;96:9827-9832.
- 51- Yuksel M, Okajima K, Uchiba M, Okabe H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. *J Pharmacol Exp Ther* 2003;305:298-305.
- 52- Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as Novel Targets for Cancer Therapy (Part III): Transcription Factors. *Am J Pharmacogenomics* 2005;5:327-338.
-